Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage III B / C / D and oligometastatic stage IV).

immunomodulators
immunologic adjuvant
cobimetinib
vemurafenib
braf v600e mutation
  • 29 views
  • 04 May, 2022
  • 3 locations
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

The main purpose of this study is to Evaluate the Efficacy and Safety of the combination of HL-085 and Vemurafenib in Advanced Melanoma Patients with BRAF V600E/K Mutation. This study includes

platelet count
braf v600e mutation
neutrophil count
vemurafenib
BRAF
  • 0 views
  • 29 Apr, 2022
  • 1 location
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

This early phase I pilot trial studies how well vemurafenib, cobimetinib, and atezolizumab work in treating patients with high-risk stage III melanoma. Vemurafenib and cobimetinib may stop the

  • 17 views
  • 04 Mar, 2022
  • 2 locations
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

include the VIC regimen (Vemurafenib + cetuximab + Irinotecan) and BEACON regimen (Encorafenib+ cetuximab +/- Binimetinib) from the SWOGS1406 study. Furthermore, BRAF inhibitor +MEK inhibitor combined

  • 0 views
  • 05 Jun, 2022
  • 1 location
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor response, the radical resectability, and the patient survival.

  • 0 views
  • 11 Oct, 2022
  • 1 location
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of

  • 202 views
  • 12 Oct, 2022
  • 72 locations
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

This is a pilot study evaluating the feasibility of using adaptive intermittent dosing of vemurafenib and cobimetinib in BRAF mutant patients with elevated baseline lactate dehydrogenase (LDH

cancer
vemurafenib
mek inhibitor
BRAF
measurable disease
  • 10 views
  • 04 Oct, 2022
  • 1 location
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)

treating with vemurafenib, trastuzumab emtansine and alectinib respectively. DARWIN II will include extensive exploratory biomarker analysis to investigate a number of genomic and immune markers

alectinib
secondary malignant neoplasm of liver
measurable disease
atezolizumab
HER2
  • 6 views
  • 11 Mar, 2022
  • 1 location
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vemurafenib and cobimetinib may stop

  • 154 views
  • 04 Oct, 2022
  • 1 location
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

ifosfamide
etoposide
cancer
fludarabine
imatinib
  • 0 views
  • 24 Jan, 2021
  • 1 location